How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Injectable Bags Market
- By Material Type: Polyvinyl Chloride (PVC), Polyolefin, Ethylene Vinyl Acetate (EVA), Polypropylene (PP)
- By Application: Intravenous (IV) Fluids, Blood Collection and Storage, Parenteral Nutrition, Chemotherapy Drug Delivery, Dialysis
- By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Home Healthcare Settings
- By Capacity: 100 ml, 250 ml, 500 ml, 1000 ml, 2000 ml
- By Sterilization Method: Ethylene Oxide (EO) Sterilization, Gamma Radiation Sterilization, Electron Beam Sterilization
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Polyvinyl Chloride (PVC) leads By Material Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Injectable Bags Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Material Type 4
Application 5
End User 4
Capacity 5
Sterilization Method 3
Companies profiled
Baxter International Inc.
Fresenius Kabi
B. Braun Melsungen AG
Nipro Corporation
Terumo Corporation
Sartorius AG
Sichuan Kelun Pharmaceutical Co. Ltd.
Sino Biopharmaceutical Limited
Jiangsu Hengrui Medicine Co. Ltd.
Becton Dickinson and Company (BD)
Pfizer Inc.
Hospira (a Pfizer company)
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Fresenius Kabi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Nipro Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Sichuan Kelun Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sino Biopharmaceutical Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Jiangsu Hengrui Medicine Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Becton Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Hospira (a Pfizer company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Nexgen Biopharma
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sartorius Stedim Biotech
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$11,896M by 2033 · 10.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Polyvinyl Chloride (PVC)46.9
- Polyolefin23.2
- Ethylene Vinyl Acetate (EVA)9.3
- Polypropylene (PP)20.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,797M → $3,770M · 9.7%
Europe$1,252M → $2,685M · 10.0%
Asia Pacific$1,143M → $2,289M · 9.1%
Latin America$707.8M → $1,428M · 9.2%
Middle East and Africa$544.5M → $1,184M · 10.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.202026
10.232027
10.242028
10.242029
10.262030
10.262031
10.282032
10.312033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Baxter International Inc.14.0
- Fresenius Kabi22.7
- B. Braun Melsungen AG13.1
- Nipro Corporation9.6
- Terumo Corporation4.8
- Sartorius AG7.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Material Type24.5%
Application18.2%
End User14.7%
Capacity29.2%
Sterilization Method13.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.2
- Europe23.6
- Asia Pacific20.2
- Latin America12.6
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Baxter International Inc. | 88 | 80 | 88 | 96 | 83 | 79 | 86 |
| Fresenius Kabi | 80 | 68 | 87 | 73 | 76 | 88 | 79 |
| B. Braun Melsungen AG | 63 | 71 | 63 | 76 | 86 | 74 | 72 |
| Nipro Corporation | 72 | 82 | 58 | 76 | 63 | 77 | 71 |
| Terumo Corporation | 74 | 55 | 73 | 64 | 56 | 54 | 63 |
| Sartorius AG | 51 | 64 | 56 | 58 | 66 | 58 | 59 |
| Sichuan Kelun Pharmaceutical Co. Ltd. | 60 | 53 | 55 | 43 | 57 | 53 | 54 |
| Sino Biopharmaceutical Limited | 35 | 47 | 40 | 52 | 56 | 47 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Baxter International Inc.
- Fresenius Kabi
- B. Braun Melsungen AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Baxter International Inc. | ✓ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Fresenius Kabi | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| B. Braun Melsungen AG | ◐ | ✓ | − | ◐ | ◐ | ◐ |
| Nipro Corporation | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Terumo Corporation | ◐ | − | ✓ | ◐ | − | − |
| Sartorius AG | − | ◐ | − | ◐ | − | − |
| Sichuan Kelun Pharmaceutical Co. Ltd. | ◐ | ◐ | − | ◐ | ◐ | − |
| Sino Biopharmaceutical Limited | − | − | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Baxter International Inc.86
2Fresenius Kabi79
3B. Braun Melsungen AG72
4Nipro Corporation71
5Terumo Corporation63
6Sartorius AG59
7Sichuan Kelun Pharmaceutical Co. Ltd.54
8Sino Biopharmaceutical Limited46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Baxter International Inc.Fresenius Kabi
Challenger2
Strong scale, closing on the leaders.
B. Braun Melsungen AGNipro Corporation
Contender2
Focused players with pockets of strength.
Terumo CorporationSartorius AG
Niche2
Specialists in a single segment or region.
Sichuan Kelun Pharmaceutical Co. Ltd.Sino Biopharmaceutical Limited
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Material Type in North America, then scale across Injectable Bags Market — a $428M beachhead inside a $6.77B market.
Beachhead (SOM)$428Mobtainable near-term
Serviceable (SAM)$2.51Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Polyvinyl Chloride (PVC)
Best fit — highest urgency & budget in Material Type.
Economic buyer76 fit
Polyolefin
Strong fit — clear ROI and a fast path to value.
End user69 fit
Ethylene Vinyl Acetate (EVA)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Material Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel29%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Material Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Injectable Bags Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified24%
Evaluation14%
Closed-won6%
$19.2KCAC
$79KLTV
4.1:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Injectable Bags Market is a resilient opportunity — $3.59B by 2033, compounding at 3.6%.
TAM · 2025$2.70Btoday
TAM · 2033$3.59Bforecast
CAGR3.6%2027–2033
Cumulative$28.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.59BTotal addressable market
SAM$1.44BServiceable available market
SOM$264MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.6% CAGR
Demand compounds through 2033, outpacing GDP across Material Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Material Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.59BLarge & growingTAM by 2033 at 3.6% CAGR
$1.44BServiceable nowreachable with today’s model
$264MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.80BBear2.3% CAGR
$3.59BBase3.6% CAGR
$4.60BBull4.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Injectable Bags Market — a $6.12B market by 2033. Plan: grow share from 8.7% to 14.0%.
Market size · 2033$6.12Btotal addressable
Market CAGR5.0%2027–2033
Target share14.0%from 8.7% today
Revenue ambition$857Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.7% | 14.0% | Ahead |
| Revenue | $579M | $857M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 36.8% | 45.1% | Ahead |
| Customer retention | 89.1% | 95.3% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Material Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Material Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $109M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Material Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Injectable Bags Market conversation — a $988M market you can size, segment and defend in minutes.
Market size · 2033$988Mtotal opportunity
Growth8.6%CAGR to 2033
Addressable buyers1,541+accounts in scope
Typical ROI5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Material Type
Goal Grow share in Material Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5×return on cost, year one
< 4 mopayback period
$65K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Baxter International Inc.Fresenius KabiB. Braun Melsungen AGNipro CorporationTerumo CorporationSartorius AGSichuan Kelun Pharmaceutical Co. Ltd.Sino Biopharmaceutical Limited+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Injectable Bags Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Injectable Bags Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Neuroprotection Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportSurgical Generators Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportSurgical Glue Market
Market size, share, segmentation and regional forecast.
$346M market · 2025 base year
View reportEcho-type Diagnostic Ultrasound Devices Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportD-type Doppler Diagnostic Ultrasound Devices Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportIntegrated Drug Discovery Service Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportIntegrated Drug Containment and Delivery Solution Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportB-type Diagnostic Ultrasound Devices Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportOne dimensional Diagnostic Ultrasound Devices Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportAddison Disease Testing Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportAdvanced Infusion Systems Market
Market size, share, segmentation and regional forecast.
$373M market · 2025 base year
View reportIntegrated Digital Operating Room Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.